Hinge Health, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
On September 30, 2026, biotech stocks PGEN, EXEL, TWST, HNGE, and PBYI hit 52-week highs. PGEN rose 6% to $9.98, EXEL reached $61.14, TWST climbed 3% to $197.19, HNGE hit $98.41, and PBYI touched $10.10. Key catalysts included clinical trial results, FDA designations, and revenue growth.
Analysts updated price targets for several companies. Piper Sandler raised Microsoft's target to $610, maintaining an Overweight rating. Other notable changes include Carmax, Accelerant, Jack Henry, Moderna, Grocery Outlet, Hinge Health, Aytu Biopharma, NetApp, and Ferrari.
Pursley James (President) sold 33,000 shares of Hinge Health, Inc. (HNGE) at an average of $94.14 ($93.37–$95.10, $3.11M total) across 3 trades on 2026-09-21 under a Rule 10b5-1 trading plan.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning HNGE (Hinge Health, Inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent HNGE coverage spans financial news, insider activity and market movers.
In the last 30 days, HNGE insiders filed 34 SEC Form 4 transactions — no purchases and 34 sales ($66.7M). The most active reporter was Mecklenburg Gabriel M.I. with 11 filings. 85% of those filings were made under pre-arranged Rule 10b5-1 plans.
Acquisition expands addressable market and supports revenue momentum.
Target raise reinforces positive outlook.
Insider sale may signal reduced confidence, likely exerting slight downward pressure on HNGE.
Fund trimming may signal reduced confidence, potentially pressuring the stock.
Insider sell following conversion.
AlphAI scores every news story that mentions HNGE with an AI model for sentiment and relevance, and aggregates insider trades from Hinge Health, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
On September 30, 2026, biotech stocks PGEN, EXEL, TWST, HNGE, and PBYI hit 52-week highs. PGEN rose 6% to $9.98, EXEL reached $61.14, TWST climbed 3% to $197.19, HNGE hit $98.41, and PBYI touched $10.10. Key catalysts included clinical trial results, FDA designations, and revenue growth.
2 min readAnalysts updated price targets for several companies. Piper Sandler raised Microsoft's target to $610, maintaining an Overweight rating. Other notable changes include Carmax, Accelerant, Jack Henry, Moderna, Grocery Outlet, Hinge Health, Aytu Biopharma, NetApp, and Ferrari.
2 min readPursley James (President) sold 33,000 shares of Hinge Health, Inc. (HNGE) at an average of $94.14 ($93.37–$95.10, $3.11M total) across 3 trades on 2026-09-21 under a Rule 10b5-1 trading plan.
1 min readOsterweis Opportunity Fund reported a 35.34% Q2 2026 return, outperforming the Russell 2000 Growth Index. Hinge Health (HNGE) was a top performer, with shares up 4.03% in the past month and 73.61% over the year. The company reported 52% year-over-year Q2 billing growth and raised guidance, but the fund noted growth may not be sustainable.
1 min readFlotek (FTK) director acquired $34.3M in shares, while Microsoft (MSFT) CFO sold $20.8M. Other insider trades include Limbach (LMB), Crocs (CROX), New Fortress (NFE), Hewlett Packard (HPE), Hinge Health (HNGE), CrowdStrike (CRWD), and Corvel (CRVL).
2 min readMecklenburg Gabriel M.I. sold 150,000 shares of Hinge Health, Inc. (HNGE) at an average of $93.22 ($88.98–$94.70, $13.98M total) across 6 trades on 2026-09-14 under a Rule 10b5-1 trading plan.
1 min readMecklenburg Gabriel M.I. sold 250,000 shares of Hinge Health, Inc. (HNGE) at an average of $88.97 ($87.02–$90.46, $22.24M total) across 5 trades on 2026-09-11 under a Rule 10b5-1 trading plan.
1 min readRelmada Therapeutics (RLMD) executives bought shares at $4.10-$4.25. PVH (PVH) CEO bought $1M in stock. Clipper Realty (CLPR) director bought $388K in shares. Gloo (GLOO) chair bought 50,000 shares. Hagerty (HGTY) sold $122M in shares. Dell (DELL) saw $55M in sales by Silver Lake. Hinge Health (HNGE) CEO sold $22.3M in shares.
2 min readHinge Health (HNGE) faces growth risks from economic downturns, acquisition integration, and competition. Hedge funds like Braidwell LP, Divisadero Street Capital, and Walleye Capital increased stakes. Jim Cramer highlights HNGE's growth potential, comparing it to a 'portfolio tight end.'
2 min readBudge James (Chief Financial Officer) sold 55,561 shares of Hinge Health, Inc. (HNGE) at an average of $89.45 ($88.22–$91.62, $4.97M total) across 5 trades on 2026-09-10 under a Rule 10b5-1 trading plan.
1 min read
